| 5.27 Data as of May 21 |  -0.01 / -0.19%Today’s Change | 4.06 Today|||52-Week Range 11.11 | -13.46% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $506.4M |
Company Description
Merrimack Pharmaceuticals, Inc. is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. Its product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. The MM-398 is a novel, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. The MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer. The MM-111 is a bispecific antibody designed to target cancer cells that are characterized by over expression of the ErbB2 cell receptor. The MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 receptor. The MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping regions, or epitopes of the epidermal growth factor receptor. The company was founded by Anthony J. Sinskey, Gavin MacBeath and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA
Employees
Shareholders
| Individual stakeholders | 6.70% |
| Mutual fund holders | 26.21% |
| Other institutional | 17.52% |
Top Executives
| Robert J. Mulroy | President, Chief Executive Officer & Director |
| William M. McClements, MBA | Senior Vice President-Operations |
| William A. Sullivan, MBA, CPA | Chief Financial Officer & Treasurer |
| Ulrik B. Nielsen, PhD | Chief Scientific Officer & Senior Vice President |
| Edward J. Stewart, MBA | Senior Vice President |
.
